SHAREHOLDER ALERT: GRABAR LAW OFFICE IS INVESTIGATING POSSIBLE MISCONDUCT AT INARI MEDICAL, INC. (NARI)

Have You Held Inari Medical Shares Continuously Since Before February 24, 2022? Learn More About Your Rights at No Cost to You.

Philadelphia, Pennsylvania--(Newsfile Corp. - October 14, 2024) - Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches at Inari Medical, Inc. (NASDAQ: NARI). If you have held Inari shares since prior to February 24, 2022, you may be entitled to:

• Corporate reforms to protect your investment.
• Reimbursement of funds to the company's coffers.
• A court-approved incentive award-all at no cost to you.

Learn More at:
https://grabarlaw.com/the-latest/inari-shareholder-investigation/, or contact Joshua Grabar at [email protected] or call 267-507-6085 for a free consultation.

Why Is Inari Medical Under Investigation?

A recently filed securities fraud class action complaint alleges the following misconduct by Inari's officers and directors:

1. Touted misleading "record revenue" claims, attributing growth to the strength of its core VTE business.
2. Failed to disclose that significant business expenses were used to improperly compensate medical professionals for using Inari products.
3. Concealed an investigation by the U.S. Department of Justice for violations of the Anti-Kickback Statute and Civil False Claims Act.
4. Misled investors about business expenses to hide improper conduct and maintain inflated stock prices.

If these allegations are true, Inari's stockholders may have been harmed from artificially inflated stock prices and mismanaged business practices.

What Can You Do Now?

If you have held Inari shares continuously since prior to February 24, 2022, you may have legal options to:

• Seek corporate reforms to ensure better governance.
• Recover funds expended by the company in defending litigation.
• Seek for a court-approved incentive award-all at no cost to you.

Take Action Today: Protect Your Investment

Learn more about your rights:
https://grabarlaw.com/the-latest/inari-shareholder-investigation/ or contact Joshua Grabar for a free consultation:

• Email: [email protected] | [email protected]
• Phone: 267-507-6085

#InariMedical #NARI $NARI #SecuritiesFraud #InvestorRights #ShareholderAlert #CorporateGovernance #FiduciaryDuty #ClassAction #GrabarLaw #LegalAction #StockMarket

Attorney Advertising Disclaimer

Contact:

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226575